FBR & Co Reaffirms “Outperform” Rating for AVEO Pharmaceuticals, Inc. (AVEO)

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)‘s stock had its “outperform” rating reaffirmed by equities research analysts at FBR & Co in a report issued on Saturday. They presently have a $3.00 price objective on the biopharmaceutical company’s stock. FBR & Co’s target price would indicate a potential upside of 417.15% from the company’s current price.

AVEO Pharmaceuticals (NASDAQ:AVEO) traded down 1.6780% during mid-day trading on Friday, reaching $0.5801. The company’s stock had a trading volume of 469,257 shares. The company’s market cap is $44.01 million. The stock’s 50 day moving average is $0.72 and its 200 day moving average is $0.68. AVEO Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $1.15.

TRADEMARK VIOLATION NOTICE: This piece was posted by BBNS and is owned by of BBNS. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://baseballnewssource.com/markets/aveo-pharmaceuticals-inc-aveo-stock-rating-reaffirmed-by-fbr-co-updated-updated/526003.html.

In other AVEO Pharmaceuticals news, major shareholder Equity Opportunities Iv Growth purchased 6,000,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 28th. The stock was bought at an average cost of $0.50 per share, with a total value of $3,000,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 5.10% of the company’s stock.

Several hedge funds have recently modified their holdings of AVEO. Renaissance Technologies LLC increased its stake in shares of AVEO Pharmaceuticals by 5.7% in the fourth quarter. Renaissance Technologies LLC now owns 2,743,900 shares of the biopharmaceutical company’s stock worth $1,482,000 after buying an additional 148,500 shares during the last quarter. Sarissa Capital Management LP purchased a new stake in AVEO Pharmaceuticals during the fourth quarter worth about $917,000. New Leaf Venture Partners L.L.C. purchased a new stake in AVEO Pharmaceuticals during the fourth quarter worth about $1,399,000. Finally, Perceptive Advisors LLC purchased a new stake in AVEO Pharmaceuticals during the fourth quarter worth about $1,678,000. 37.94% of the stock is owned by institutional investors.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

5 Day Chart for NASDAQ:AVEO

Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 

Latest News

Sources Say Luis Robert Will Be Cleared by May 20 to Sign
Sources Say Luis Robert Will Be Cleared by May 20 to Sign
Colorado Rockies Bullpen Helping Them to NL West Lead
Colorado Rockies Bullpen Helping Them to NL West Lead
Hall of Famer Given New Lease on Life
Hall of Famer Given New Lease on Life
New York Mets Have the Power
New York Mets Have the Power
Red Sox Fighting Through Illness and Injury
Red Sox Fighting Through Illness and Injury
Cleveland and Arizona Off to Fast Starts
Cleveland and Arizona Off to Fast Starts


Leave a Reply

 
© 2006-2017 BBNS.